These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3755864)

  • 1. Treatment of myelodysplastic syndrome with 1.25-dihydroxy-vitamin D3.
    Richard C; Mazo E; Cuadrado MA; Iriondo A; Bello C; Gandarillas MA; Zubizarreta A
    Am J Hematol; 1986 Oct; 23(2):175-8. PubMed ID: 3755864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells.
    Koeffler HP; Hirji K; Itri L
    Cancer Treat Rep; 1985 Dec; 69(12):1399-407. PubMed ID: 2416438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of myelodysplastic syndrome and acute myelogenous leukemia with vitamin D3 [1 alpha(OH)D3]].
    Irino S; Taoka T
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1183-90. PubMed ID: 2837981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined differentiation therapy in myelodysplastic syndrome with retinoid acid, 1 alpha,25 dihydroxyvitamin D3, and prednisone.
    Blazsek I; Musset M; Boulé D; Labat ML; Bringuier MF; Comisso M; Le Maignan C; Ribaud P; Mathé G; Misset JL
    Cancer Detect Prev; 1992; 16(4):259-64. PubMed ID: 1458517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 1,25-dihydroxyvitamin D3 and 13-cis-retinoic acid on in vitro hematopoiesis in the myelodysplastic syndromes.
    Nagler A; Rikilis I; Tatarsky I; Fabian I
    J Lab Clin Med; 1987 Aug; 110(2):237-44. PubMed ID: 3474327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D treatment in myelodysplastic syndromes.
    Mellibovsky L; Díez A; Pérez-Vila E; Serrano S; Nacher M; Aubía J; Supervía A; Recker RR
    Br J Haematol; 1998 Mar; 100(3):516-20. PubMed ID: 9504634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
    Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
    Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of bone marrow cells from myelodysplastic patients in the presence of 1,25 dihydroxyvitamin D3 or 13-cis retinoic acid.
    Nagler A; Ricklis I; Gazit E; Tatarsky I; Fabian I
    Eur J Clin Invest; 1986 Aug; 16(4):297-301. PubMed ID: 3093242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia.
    Radujkovic A; Schnitzler P; Ho AD; Dreger P; Luft T
    Clin Nutr; 2017 Apr; 36(2):542-551. PubMed ID: 26899917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial.
    Negrin RS; Haeuber DH; Nagler A; Olds LC; Donlon T; Souza LM; Greenberg PL
    Ann Intern Med; 1989 Jun; 110(12):976-84. PubMed ID: 2471429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of myelodysplastic syndrome and acute myelogenous leukemia with vitamin D3 (1 alpha(OH)D3)].
    Taoka T; Hamamoto T; Okuda Y; Hata Y; Kubota Y; Tanaka T; Irino S; Miyazaki T; Ohbayashi S
    Rinsho Ketsueki; 1987 Jun; 28(6):830-8. PubMed ID: 3478504
    [No Abstract]   [Full Text] [Related]  

  • 14. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
    Pilatrino C; Cilloni D; Messa E; Morotti A; Giugliano E; Pautasso M; Familiari U; Cappia S; Pelicci PG; Lo Coco F; Saglio G; Guerrasio A
    Cancer; 2005 Jul; 104(1):101-9. PubMed ID: 15895376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cyclosporine A based therapy for myelodysplastic syndrome].
    Li ZL; Gong M; Xu SH; Huang FZ; Chen YR; Ma YG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):867-70. PubMed ID: 16277860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice.
    Zhou JY; Norman AW; Chen DL; Sun GW; Uskokovic M; Koeffler HP
    Proc Natl Acad Sci U S A; 1990 May; 87(10):3929-32. PubMed ID: 2339131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 13-cis retinoic acid treatment for myelodysplastic syndromes.
    Picozzi VJ; Swanson GF; Morgan R; Hecht F; Greenberg PL
    J Clin Oncol; 1986 Apr; 4(4):589-95. PubMed ID: 3514807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome.
    Ferrero D; Campa E; Dellacasa C; Campana S; Foli C; Boccadoro M
    Haematologica; 2004 May; 89(5):619-20. PubMed ID: 15136232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia.
    Nimer SD; Paquette RL; Ireland P; Resta D; Young D; Golde DW
    Exp Hematol; 1994 Aug; 22(9):875-80. PubMed ID: 8062886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Is 1,25(OH)2D3 effective in chronic osteomyelofibrosis?].
    Eugster C; Brun del Re GP; Bucher U
    Schweiz Med Wochenschr; 1986 Dec; 116(50):1767-70. PubMed ID: 3798067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.